0001104659-25-059403.txt : 20250613 0001104659-25-059403.hdr.sgml : 20250613 20250613163135 ACCESSION NUMBER: 0001104659-25-059403 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250611 FILED AS OF DATE: 20250613 DATE AS OF CHANGE: 20250613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hahn Mark W CENTRAL INDEX KEY: 0001408502 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38067 FILM NUMBER: 251047126 MAIL ADDRESS: STREET 1: 6340 QUADRANGLE DRIVE STREET 2: SUITE 100 CITY: CHAPEL HILL STATE: NC ZIP: 27517 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verona Pharma plc CENTRAL INDEX KEY: 0001657312 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 MORE LONDON RIVERSIDE CITY: LONDON STATE: X0 ZIP: SE1 2RE BUSINESS PHONE: 011-44-0-2032834200 MAIL ADDRESS: STREET 1: 3 MORE LONDON RIVERSIDE CITY: LONDON STATE: X0 ZIP: SE1 2RE 4 1 tm2517862-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2025-06-11 0 0001657312 Verona Pharma plc VRNA 0001408502 Hahn Mark W 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE UNITED KINGDOM 0 1 0 0 Chief Financial Officer 1 Ordinary Shares 2025-06-11 4 S 0 400000 11.4009 D 12278992 D Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted on January 29, 2025. The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $11.375 to $11.4575 per Ordinary Share, inclusive (or $91.00 to $91.66 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Consists of (i) 2,450,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 306,250 ADSs); and (ii) 9,828,992 Ordinary Shares underlying 1,228,624 ADSs. /s/ Andrew Fisher, Attorney-in-fact for Mark Hahn 2025-06-13